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Case Report
AbstractPrimary gliosarcoma (PGS) is rare and is known for extra cranial metastases. Theoverall outcome is dismal and hence the focus is on providing the best quality oflife. This report describes a seventy-year-old lady who at presentation hadmetastatic primary gliosarcoma with intractable cough. Her lung lesion was treatedwith stereotactic body radiotherapy (SBRT) to a dose of 10 Gray per fraction forthree consecutive days. She was free of cough till her death at eighteen monthsafter treatment. This is probably the first reported case of excellent long-termquality of life in a patient of metastatic primary gliosarcoma.
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1. IntroductionGliosarcoma (GS) constitutes 1.8-2.8% of allglioblastoma multiforme (GBM).1 It can be primarywhen it occurs “de novo” as opposed to secondary wheninitially the patient was treated as glioma andsubsequently the recurrence reveals gliosarcoma.2 Inaddition to histologically resembling GBM, it also showsmesenchymal component which resembles fibroblast,cartilage, bone, smooth muscle, striated muscle oradipose tissue.3 Due to the sarcomatous component,they are prone for extracranial metastasis, mostcommon sites being liver, lung and bone.4 Themesenchymal element is the reason for its poorprognosis compared to GBM. The treatment is same asthat of GBM which includes maximum safe resectionfollowed by adjuvant radiation and temozolamide.5From a single institute in India, Kumar et al.6 conductedan audit of 24 patients and found that the overallsurvival was similar, 7.3 and 7.5 Months with GS andGBM respectively. Maximum time to disease progressionis 11 months and longest survival described in theliterature is 18 months.5Majority of the times, the emphasis is on the cancerdirected therapy and relatively less importance is givento the worsening symptoms. Also the therapy itself hasits own acute sequelae that may add to the alreadycompromised quality of life. Hence, it is very importantto employ treatments that are more effective and leasttoxic. Hypo fractionation with stereotactic body
radiotherapy (SBRT) delivers high dose in short timewith minimal toxicity. This is an attempt to present acase report of a metastatic primary gliosarcoma whohad complete relief from cough until her death.
2. Methods and MaterialsA 73-year-old lady presented with weakness of righthand of 20 days duration. She was diabetic since last tenyears, hypertensive since one year and asthmatic forpast five years and was on regular medication. She wasinvestigated with magnetic resonance imaging (MRI)and underwent gross total excision of a space-occupyinglesion arising from the left parietal region. Thepostoperative histopathology was grade IV Gliosarcoma.Patient was taken up for adjuvant radiation 40 Gy/20fraction with 3-dimensional conformal radiotherapytechnique (3DCRT) along with temozolamide. Patienthad persistent cough and hence a chest x-ray was donewhich revealed a lesion in the midzone of right lung. Thecough was persistent and the patient was not able tosleep which severely compromised her quality of life.Patient was subsequently taken up for SBRT, boost tothe tumor bed and palliative radiation to the lung lesion.The planning positron emission tomography (PET) scanpicked up additional lesions in the left gluteal region andright upper thigh, both were asymptomatic and hencekept under observation.
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2.1. Stereotactic body radiotherapyThree gold fiducials were placed in and around the lunglesion and radiotherapy planning was done seven dayslater. Patient was immobilized with orifit cast for thehead and vacloc for the lung treatment. Simulation wasdone using computerized tomography (CT), MRI as wellas PET scan. Images of CT /MR were fused forcontouring brain lesion and CT/PET images were usedto contour lung lesion. PET detected lung lesion wascontoured as gross tumour volume. Spinal cord, lungs,heart, great vessels, esophagus and tracheobronchialtree were contoured as organs at risk. A plan wasgenerated on multi plan treatment planning system(TPS) using ray tracing algorithm. The dose received by
the tumour as well as normal structures (Figure 1) wasevaluated qualitatively in axial, coronal and sagittalsections (Figure 2-4) and quantitatively using dosevolume histograms (Figure 5). Patient was treated to adose of 10 Gy per fraction prescribed at 82%, forconsecutive three days. A total of 247 beams were usedat 87 different nodal stations as shown (Figure 6).Intrafraction verification was done tracking the fiducialsand synchrony system was used to monitor respiration.Patient had severe cough during the first fraction, thetreatment had to be interrupted many times and hencetook a longer time. However, subsequent fractions wereuneventful. Patient also received boost dose of radiationto the brain lesion to a dose of 12 Gy in two fractions.
Figure 1: Table showing dose received by gross tumour and different organs at risk.
Figure 2: Axial section of the chest showing localized high dose to the tumour.
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Figure 3: Coronal section of the chest showing dosedistribution sparing the heart.
Figure 4: Sagittal section of the chest showing focused dosedelivery sparing majority of the lung.
Figure 5: Dose volume histograms showing clear separation of the curves, normal structures on the left and tumour on theright.
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Figure 6: Three dimensional view of chest showing radiation beam entering from different angles.
3. Results and DiscussionShe was on regular follow up and had complete relieffrom cough. PET scan done six months later showedreduction in lung lesion size, however the soft tissuelesions had increased in size but patient still remainedasymptomatic. She was alive for 18 months afterdiagnosis when she died of myocardial infarction andwas completely free of cough until her death.Quality of life is the most important aspect of ametastatic disease. The emphasis to achieve this is onemploying treatment modalities that are highly effectiveand at the same time less toxic for the patient. SBRT isone such radiation technique wherein multiple beamsfrom different angles are used to focus on a particularpoint. Thus, it deposits maximum dose around that pointand the surrounding normal structures get minimaldose, reducing the rate of complications. This isclassically used in small tumours less than three cms,relatively radio resistant tumours, which require higherdoses, and those tumours that are situated near criticalstructures. Our patient typically had all these factors andhence was treated with SBRT.Cyber knife is a robotically controlled miniature linearaccelerator with real time image guidance. Real timeimage guidance software and the robot in the cyberknife continuously tracks and adjusts for movementduring the entire treatment. Multiple sets of orthogonalx-rays are taken, fiducials are tracked, and observedvariations are corrected before the radiation is actuallydelivered. Different phases of breathing cycle are
captured onto the computer with the help of fibre opticcables and light emitting diode’s (LED) on the jacket thatpatient wears during treatment. The synchrony softwareidentifies the tumour in relation to different phases ofbreathing cycle. Hence, it is possible to treat the tumourduring a particular phase of breathing and there is noneed of respiratory gating.The long-term palliation of cough was due to the highdose delivered to the lesion and the reduction in sizewas documented with a subsequent PET scan. In aretrospective study, Christina et al have analyzed therole of SBRT for inoperable metastasis from primarysarcoma and have concluded that it is safe, convenientand effective and observed a median survival of 14.2Months.7To our knowledge, this report is the first of its kind,which demonstrates long-term palliation of cough and isgratifying not only to the patient but also to thepalliative caregivers.
4. ConclusionPrimary gliosarcoma is an aggressive tumour and isassociated with a poor outcome. Cough as a symptom ofmetastatic cancer is very difficult to treat and reducesthe quality of life of a terminally ill patient. Selectedpatients do have long-term palliation from SBRT whichhas the advantage of higher dose delivery over shorterduration of treatment and also is not associated with anycomplications.
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